Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Closed-Loop/Automated Insulin Delivery (Next-Gen) Market: Screenless Smartphone-Controlled System Demand, Dual Glucose-Ketone Sensing Growth, and Insulin-Deficient Type 2 Diabetes Eligibility Adoption to Drive Strong Market Expansion Through 2035

The global Closed-Loop/Automated Insulin Delivery (Next-Gen) Market is projected to expand at a strong CAGR of 14.2% through 2035, driven by sustained demand for screenless, smartphone-controlled automated insulin delivery systems, growing adoption of dual glucose-ketone sensing technology, and continued expansion of treatment eligibility beyond type 1 diabetes into insulin-treated type 2 and other insulin-deficient diabetes. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises established commercial systems including MiniMed 780G, Omnipod 5, and Tandem t:slim X2 with Control-IQ, alongside next-generation platforms such as MiniMed Flex and the iLet Bionic Pancreas.

The market’s strong 14.2% CAGR reflects continued technological evolution against a global type 1 diabetes population estimated at 9.5 million people in 2025, a figure that continues to expand alongside a substantial and growing insulin-treated type 2 diabetes population now recognized as eligible for automated insulin delivery under the American Diabetes Association’s 2026 standards of care. The MiniMed Flex, smaller than the 780G, screenless, smartphone-controlled, and built around an adaptive real-time insulin-adjustment algorithm, illustrates the field’s continued push toward more autonomous, less burdensome diabetes management, while Abbott’s August 2026 FDA authorization of Libre Duo, a sensor providing continuous glucose and rising-ketone detection, points toward a coming generation of multi-analyte-integrated automated delivery systems. Coverage extending across multiple automation levels, algorithm technologies, and patient populations underscores the breadth of clinical and commercial infrastructure now supporting this maturing but still rapidly evolving category.

Executive Snapshot

How does screenless smartphone-controlled system demand drive the next-gen automated insulin delivery market?
Diabetes specialty centers and patients increasingly favor screenless, smartphone-controlled systems such as MiniMed Flex, which uses an adaptive algorithm for real-time insulin adjustment and automatic correction, establishing this device architecture as a defining next-generation commercial differentiator. As this design philosophy continues to spread across competing platforms, procurement associated with screenless, app-controlled systems is expected to increasingly exceed levels attributable to conventional pump-controlled interfaces.

What role does dual glucose-ketone sensing growth play in market expansion?
Biopharmaceutical and device developers continue to advance multi-analyte sensing technology following Abbott’s August 2026 FDA authorization of Libre Duo, which continuously monitors glucose while detecting rising ketones, sustaining structured demand from developers pursuing integrated safety monitoring beyond glucose alone as a foundation for more autonomous closed-loop control.

How does insulin-deficient type 2 diabetes eligibility adoption sustain market growth?
Diabetes treatment centers increasingly extend automated insulin delivery beyond its historical type 1 diabetes core, consistent with the American Diabetes Association’s 2026 standards recognizing its use in insulin-treated type 2 diabetes and other insulin-deficient diabetes, sustaining structured demand from developers and clinicians pursuing this substantially larger addressable patient population.

What is driving demand for automated insulin delivery in unannounced-meal handling applications?
Developers pursuing automated meal detection and unannounced-meal handling algorithms continue to extend closed-loop technology beyond current systems that still generally require some form of manual carbohydrate input, generating incremental demand among device developers pursuing greater patient independence from meal announcement burden.

How does interoperable and open-source AID architecture demand sustain the market?
Patients and treatment centers increasingly value interoperable pump and CGM components alongside open-source automated insulin delivery approaches, sustaining structured demand from developers pursuing modular, multi-vendor ecosystem compatibility relative to proprietary closed systems.

Which closed-loop automated insulin delivery market segments are growing fastest?
The fastest-growing segments include screenless smartphone-controlled systems, multi-analyte and dual glucose-ketone sensing technology, insulin-treated type 2 diabetes patient populations, and AI-based and machine-learning dosing algorithms.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Closed-Loop/Automated Insulin Delivery (Next-Gen) Market

  • Clinical and disease data snapshot sustaining the evidentiary foundation for the category’s growth outlook: The global type 1 diabetes population reached an estimated 9.5 million people in 2025, up 13% since 2021; the American Diabetes Association’s 2026 standards now recognize automated insulin delivery for insulin-treated type 2 and other insulin-deficient diabetes; and Abbott’s Libre Duo sensor, authorized by the FDA in August 2026, adds continuous ketone detection alongside glucose monitoring.
  • Hybrid closed-loop and advanced hybrid closed-loop systems sustaining the leading share of current commercial activity: MiniMed 780G, Omnipod 5, and Tandem Control-IQ-enabled systems continue to anchor the substantial majority of current automated insulin delivery commercial revenue.
  • Screenless, smartphone-controlled architecture sustaining structured demand above conventional pump-display interfaces: The MiniMed Flex’s design approach continues to represent a meaningful next-generation differentiator within the competitive landscape.
  • Type 1 diabetes sustaining the largest current patient population while insulin-treated type 2 diabetes expands eligibility: This established core population continues to anchor commercial demand as broader clinical guidelines extend automated insulin delivery eligibility.
  • Multi-analyte and dual-hormone sensing sustaining structured next-generation technology demand growth: Glucose-ketone sensing and emerging insulin-plus-amylin or insulin-plus-glucagon delivery concepts continue to represent important areas of platform innovation.
  • AI-based and adaptive dosing algorithms sustaining structured demand above conventional PID and MPC control approaches: Machine-learning and reinforcement-learning-based insulin dosing continue to attract developer investment pursuing improved personalization and reduced patient burden.

Market Segmentation: Closed-Loop/Automated Insulin Delivery (Next-Gen) Market

By System Type
  • Hybrid Closed-Loop / AID
  • Advanced hybrid closed-loop
  • Fully automated insulin delivery
  • Predictive low-glucose suspend
  • Automated basal insulin delivery
  • Automated correction-dose systems
  • Open-source AID
  • Interoperable AID systems
By Product
  • MiniMed 780G
  • MiniMed Flex
  • Omnipod 5
  • Tandem t:slim X2 with Control-IQ
  • Tandem Mobi with Control-IQ
  • iLet Bionic Pancreas
  • CamAPS / compatible systems
  • Others
By Insulin Delivery Architecture
  • Tubed insulin pump
  • Tubeless / patch pump
  • Wearable patch pump
  • Disposable patch pump
  • Implantable pump
  • Hybrid wearable systems
  • Other delivery architectures
By Automation Level
  • Manual insulin delivery
  • Low-glucose suspend
  • Predictive low-glucose suspend
  • Automated basal adjustment
  • Automated basal + correction
  • Hybrid closed-loop
  • Advanced hybrid closed-loop
  • Fully automated closed-loop
  • Autonomous meal management
By CGM Integration
  • Integrated proprietary CGM
  • Interoperable CGM
  • Real-time CGM
  • Factory-calibrated CGM
  • Flash/other glucose sensing
  • Multi-CGM compatibility
  • Future multi-biomarker sensing
By Insulin Delivery Mode
  • Rapid-acting insulin
  • Ultra-rapid insulin
  • Standard rapid-acting analogs
  • Concentrated insulin
  • Dual-hormone delivery
  • Insulin + glucagon
  • Insulin + pramlintide/amylin
  • Multi-hormonal delivery
By Age Group
  • <7 years
  • 7–12 years
  • 13–17 years
  • 18–44 years
  • 45–64 years
  • 65+ years
By Distribution Channel
  • Hospital procurement
  • Specialty pharmacy
  • Retail pharmacy
  • Durable medical equipment suppliers
  • Direct-to-consumer
  • Diabetes technology distributors
  • Online / e-commerce
  • Insurance-supported distribution
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Hospitals
  • Endocrinology clinics
  • Diabetes specialty centers
  • Pediatric diabetes centers
  • Primary-care clinics
  • Home healthcare
  • Telehealth providers
  • Patients / caregivers
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Closed-Loop/Automated Insulin Delivery (Next-Gen) Market

  1. Sustained global type 1 diabetes population growth driving continued automated insulin delivery adoption: An estimated 9.5 million people living with type 1 diabetes in 2025 continues to support structured demand above the discretionary medical device baseline.
  2. Growing clinical guideline recognition supporting expanded eligibility into insulin-treated type 2 diabetes: The American Diabetes Association’s 2026 standards continue to broaden the category’s addressable patient population beyond type 1 diabetes alone.
  3. Continued device innovation supporting screenless, smartphone-controlled system adoption: The MiniMed Flex’s design approach continues to attract structured patient and clinician interest in reduced device burden.
  4. Sustained technology investment in multi-analyte sensing supporting dual glucose-ketone monitoring adoption: Libre Duo’s August 2026 FDA authorization continues to support structured developer investment in integrated safety-monitoring sensor technology.
  5. Growing algorithm sophistication supporting AI-based and adaptive insulin dosing adoption: Machine-learning and reinforcement-learning dosing approaches continue to attract developer investment pursuing improved personalization and reduced patient burden.
  6. Maturing interoperability standards supporting open-source and multi-vendor ecosystem development: Continued FDA classification of interoperable automated glycemic controllers continues to focus industry attention on the category’s modular ecosystem evolution.

Regional Outlook: Closed-Loop/Automated Insulin Delivery (Next-Gen) Market

  • North America: The United States accounts for the largest share of regional demand, anchored by broad payer coverage, extensive endocrinology and diabetes specialty center infrastructure, and the commercial presence of all leading automated insulin delivery platforms; regional treatment centers continue to expand technology adoption capacity to accommodate this demand.
  • Europe: Germany, the United Kingdom, and France anchor regional demand, supported by growing specialized diabetes technology center capacity and CE-marked availability of leading automated insulin delivery systems; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and India, which rank among the countries with the largest global type 1 diabetes populations, anchor some of the fastest-growing regional markets as automated insulin delivery access continues to expand; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil represents an emerging regional demand base given its ranking among the countries with the largest global type 1 diabetes populations, as specialized diabetes centers begin to expand automated insulin delivery access; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Closed-Loop/Automated Insulin Delivery (Next-Gen) Market

Key Players
Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., Abbott Laboratories, Dexcom, Inc., CamDiab Ltd.

  • Medtronic plc [March 2026] — confirmed continued commercial rollout of MiniMed Flex, its screenless, smartphone-controlled automated insulin delivery system, with the company noting sustained patient and clinician interest in its adaptive dosing algorithm.
  • Abbott Laboratories [August 2026] — confirmed FDA authorization of Libre Duo, a continuous sensor providing simultaneous glucose monitoring and rising-ketone detection, with the company noting this represents a foundational step toward next-generation multi-analyte automated insulin delivery integration.
  • Beta Bionics, Inc. [December 2025] — reported continued commercial expansion of the iLet Bionic Pancreas, with the company noting sustained demand from patients seeking simplified, largely weight-based dosing without conventional carbohydrate counting.

Consultant POV

The Closed-Loop/Automated Insulin Delivery (Next-Gen) Market’s strong 14.2% CAGR outlook through 2035 is anchored in sustained demand for screenless smartphone-controlled systems, growing dual glucose-ketone sensing activity, and continued expansion of eligibility into insulin-deficient type 2 diabetes, set against a global type 1 diabetes population of an estimated 9.5 million people in 2025. Sustained device and software investment from companies including Medtronic plc, Insulet Corporation, and Abbott Laboratories confirms the Closed-Loop/Automated Insulin Delivery Market will sustain strong growth through 2035.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report